Summit Therapeutics — Q3 2026 Earnings Summary

Summit Therapeutics reported a $2 billion strategic equity investment from AstraZeneca and announced a PDUFA goal date of November 14, 2026, for its Biologics License Application seeking approval for ivonescimab in EGFR-mutated non-squamous non-small cell lung cancer. The company's clinical program continues to expand with new studies in bladder, kidney, and biliary tract cancers, while interim data from Akeso's HARMONi-2 and HARMONi-GI1 trials demonstrated statistically significant overall survival benefits for ivonescimab compared to pembrolizumab and durvalumab, respectively. For the third quarter of 2026, Summit recorded GAAP operating expenses of $214.6 million and a net loss of $208.4 million, ending the period with $629.8 million in cash and investments.